Abstract
Transglutaminases are a large family of related and ubiquitous enzymes which catalyze the cross-linking of a glutaminyl residue of a protein/peptide substrate to a lysyl residue of a protein/peptide co-substrate. These enzymes are also capable of catalyzing other reactions important for the cell viability. The distribution and the physiological roles of the human transglutaminases have been widely studied in numerous cell types and tissues and their roles in several diseases have begun to be identified. Recently, “tissue” transglutaminase (TG2) has been shown to be involved in the molecular mechanisms responsible for a very widespread human pathology, Celiac Disease (CD). Transglutaminase activity has also been hypothesized to be directly involved in the pathogenetic mechanisms responsible for several human neurodegenerative diseases, which are characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked proteins in affected brains, such as Alzheimers disease (AD), Parkinsons disease (PD), supranuclear palsy, Huntingtons disease (HD) and other recently identified polyglutamine diseases. In this review we discuss the biochemistry of the transglutaminases, with particular reference to the molecular mechanisms that could be involved in the physiopathological processes responsible for these human neurodegenerative diseases.
Keywords: Transglutaminases, post-translational modifications of proteins, neurodegenerative diseases, transglutaminase inhibitors
CNS & Neurological Disorders - Drug Targets
Title: Transglutaminase-Catalyzed Post-Translational Modifications of Proteins in the Nervous System and their Possible Involvement in Neurodegenerative Diseases
Volume: 7 Issue: 4
Author(s): G. De Vivo and V. Gentile
Affiliation:
Keywords: Transglutaminases, post-translational modifications of proteins, neurodegenerative diseases, transglutaminase inhibitors
Abstract: Transglutaminases are a large family of related and ubiquitous enzymes which catalyze the cross-linking of a glutaminyl residue of a protein/peptide substrate to a lysyl residue of a protein/peptide co-substrate. These enzymes are also capable of catalyzing other reactions important for the cell viability. The distribution and the physiological roles of the human transglutaminases have been widely studied in numerous cell types and tissues and their roles in several diseases have begun to be identified. Recently, “tissue” transglutaminase (TG2) has been shown to be involved in the molecular mechanisms responsible for a very widespread human pathology, Celiac Disease (CD). Transglutaminase activity has also been hypothesized to be directly involved in the pathogenetic mechanisms responsible for several human neurodegenerative diseases, which are characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked proteins in affected brains, such as Alzheimers disease (AD), Parkinsons disease (PD), supranuclear palsy, Huntingtons disease (HD) and other recently identified polyglutamine diseases. In this review we discuss the biochemistry of the transglutaminases, with particular reference to the molecular mechanisms that could be involved in the physiopathological processes responsible for these human neurodegenerative diseases.
Export Options
About this article
Cite this article as:
De Vivo G. and Gentile V., Transglutaminase-Catalyzed Post-Translational Modifications of Proteins in the Nervous System and their Possible Involvement in Neurodegenerative Diseases, CNS & Neurological Disorders - Drug Targets 2008; 7 (4) . https://dx.doi.org/10.2174/187152708786441821
DOI https://dx.doi.org/10.2174/187152708786441821 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Measuring Receptor Occupancy with PET
Current Pharmaceutical Design Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Delivering RNA Interference to the Mammalian Brain
Current Gene Therapy Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design Post-stroke Engagement-sensitive Balance Rehabilitation Under An Adaptive Multi-level Electrotherapy: Clinical Hypothesis and Computational Framework
Neuroscience and Biomedical Engineering (Discontinued) Role of PACAP in Neural Stem/Progenitor Cell and Astrocyte: from Neural Development to Neural Repair
Current Pharmaceutical Design Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Alzheimers Disease - An Interactive Perspective
Current Alzheimer Research Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Neurological Substrate of Central Auditory Processing Deficits in Children
Current Pediatric Reviews Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T)
Current Genomics Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia
Current Pharmaceutical Design Transglutaminase Activity as a Possible Therapeutical Target in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care
Current Neuropharmacology Biofilm Formation by Candida albicans is Inhibited by 4,4-Dichloro Diphenyl Diselenide (pCl-PhSe)<sub>2</sub>
Current Drug Discovery Technologies Cerebral White Matter Injuries Following a Hypoxic/Ischemic Insult During the Perinatal Period: Pathophysiology, Prognostic Factors, and Future Strategy of Treatment Approach. A Minireview
Current Pharmaceutical Design Genetics of Schizophrenia and other Psychotic Disorders
Current Psychiatry Reviews